Walleye Capital LLC Makes New $605,000 Investment in Sionna Therapeutics, Inc. $SION

Walleye Capital LLC bought a new stake in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) in the first quarter, Holdings Channel reports. The fund bought 15,097 shares of the company’s stock, valued at approximately $605,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Russell Investments Group Ltd. acquired a new stake in shares of Sionna Therapeutics in the third quarter worth approximately $30,000. BNP Paribas Financial Markets acquired a new position in Sionna Therapeutics in the 2nd quarter valued at $31,000. GF Fund Management CO. LTD. acquired a new position in Sionna Therapeutics in the 4th quarter valued at $36,000. Balyasny Asset Management L.P. purchased a new position in Sionna Therapeutics in the 4th quarter valued at $58,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Sionna Therapeutics in the 4th quarter valued at $89,000.

Sionna Therapeutics Trading Up 3.7%

Shares of NASDAQ:SION opened at $45.70 on Friday. The company has a market capitalization of $2.06 billion, a PE ratio of -23.68 and a beta of 1.33. Sionna Therapeutics, Inc. has a twelve month low of $16.38 and a twelve month high of $51.56. The firm has a 50 day simple moving average of $41.04 and a 200-day simple moving average of $39.79.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). As a group, equities research analysts predict that Sionna Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Peter A. Thompson sold 85,918 shares of Sionna Therapeutics stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the sale, the director owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. The trade was a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the sale, the director directly owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. The trade was a 3.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 989,630 shares of company stock valued at $44,987,483. 5.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Citizens Jmp reaffirmed a “market outperform” rating and set a $63.00 target price on shares of Sionna Therapeutics in a report on Tuesday, May 26th. JonesTrading raised their price target on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Stifel Nicolaus boosted their price target on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, May 18th. Freedom Capital lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Finally, BTIG Research reaffirmed a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a research note on Wednesday, May 13th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Sionna Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $53.22.

Sionna Therapeutics Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.